Illumina to pay $8 bln for Jeff Bezos-backed cancer testing firm Grail
Sept 21 (Reuters) - Gene sequencing company Illumina Inc ILMN.O will pay $8 billion in cash and stock to buy cancer screening startup Grail Inc, the companies said on Monday.
Grail, which is developing a blood test to identify early-stage cancers, was founded by Illumina as a separate company in 2016 and is backed by Amazon.com Inc AMZN.O founder Jeff Bezos and billionaire philanthropist Bill Gates.
The deal would give Illumina access to Grail's test for early detection of cancer from blood called Galleri, which is expected to launch commercially in 2021.
Grail plans to follow Galleri with future blood-based tests for cancer diagnosis, detection and post-treatment monitoring of cancer patients, the companies said.
Earlier this month Grail, in which Illumina is the biggest shareholder with a near 14.5% stake, filed for a U.S. initial public offering, without disclosing the offering size.
Under the terms of the agreement, Grail stockholders, including Illumina, will receive $3.5 billion in cash and $4.5 billion in shares of Illumina common stock.
Grail stockholders will also receive future payments representing a tiered single-digit percentage of certain Grail-related revenue.
Min kommentar
Striden om den kommande motorn för cancerdiagnostik är avgjord. Bjässen fick som den ville och slukade guldägget med hull och hår.Men hav tröst alla investerare från USA.Med lite tålamod kan ni få vara med på en annan investeringsrunda med minst lika bra troligt utfall,kanske bättre än Grail hade kunnat åstadkomma på börsen.Googla upp PHI och kontaktvägen till VD Egelberg.Be att få allokera nån miljard $ till den kommande noteringen av GlycoImaging.Har ni tur kanske VD går med på det.
Ps. Hälsa från the99
Mvh the99
Inga kommentarer:
Skicka en kommentar